Long-term vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model
- PMID: 22897930
- PMCID: PMC3505228
- DOI: 10.1111/j.1750-2659.2012.00423.x
Long-term vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model
Abstract
Background: Highly pathogenic H5N1 influenza viruses reemerged in humans in 2003 and have caused fatal human infections in Asia and Africa as well as ongoing outbreaks in poultry. These viruses have evolved substantially and are now so antigenically varied that a single vaccine antigen may not protect against all circulating strains. Nevertheless, studies have shown that substantial cross-reactivity can be achieved with H5N1 vaccines. These studies have not, however, addressed the issue of duration of such cross-reactive protection.
Objectives: To directly address this using the ferret model, we used two recommended World Health Organization H5N1 vaccine seed strains - A/Vietnam/1203/04 (clade 1) and A/duck/Hunan/795/02 (clade 2.1) - seven single, double, or triple mutant viruses based on A/Vietnam/1203/04, and the ancestral viruses A and D, selected from sequences at nodes of the hemagglutinin and neuraminidase gene phylogenies to represent antigenically diverse progeny H5N1 subclades as vaccine antigens.
Results: All inactivated whole-virus vaccines provided full protection against morbidity and mortality in ferrets challenged with the highly pathogenic H5N1 strain A/Vietnam/1203/04 5 months and 1 year after immunization.
Conclusion: If an H5N1 pandemic was to arise, and with the hypothesis that one can extrapolate the results from three doses of a whole-virion vaccine in ferrets to the available split vaccines for use in humans, the population could be efficiently immunized with currently available H5N1 vaccines, while the homologous vaccine is under production.
© 2012 John Wiley & Sons Ltd.
Figures

Similar articles
-
Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets.Vaccine. 2009 Jun 24;27(31):4187-95. doi: 10.1016/j.vaccine.2009.04.050. Epub 2009 May 9. Vaccine. 2009. PMID: 19406182 Free PMC article.
-
Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.J Virol. 2017 Jul 12;91(15):e00547-17. doi: 10.1128/JVI.00547-17. Print 2017 Aug 1. J Virol. 2017. PMID: 28490598 Free PMC article.
-
Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models.J Gen Virol. 2014 Apr;95(Pt 4):793-798. doi: 10.1099/vir.0.058636-0. Epub 2014 Jan 13. J Gen Virol. 2014. PMID: 24421115
-
Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.BioDrugs. 2008;22(5):279-92. doi: 10.2165/00063030-200822050-00001. BioDrugs. 2008. PMID: 18778110 Review.
-
The current state of H5N1 vaccines and the use of the ferret model for influenza therapeutic and prophylactic development.J Infect Dev Ctries. 2012 Jun 15;6(6):465-9. doi: 10.3855/jidc.2666. J Infect Dev Ctries. 2012. PMID: 22706187 Review.
Cited by
-
Quantitative measurement of influenza virus replication using consecutive bronchoalveolar lavage in the lower respiratory tract of a ferret model.J Vet Sci. 2014;15(3):439-42. doi: 10.4142/jvs.2014.15.3.439. Epub 2014 Apr 2. J Vet Sci. 2014. PMID: 24690606 Free PMC article.
-
The Quest for a Truly Universal Influenza Vaccine.Front Cell Infect Microbiol. 2019 Oct 10;9:344. doi: 10.3389/fcimb.2019.00344. eCollection 2019. Front Cell Infect Microbiol. 2019. PMID: 31649895 Free PMC article. Review.
-
Avian Influenza A Virus Pandemic Preparedness and Vaccine Development.Vaccines (Basel). 2018 Jul 25;6(3):46. doi: 10.3390/vaccines6030046. Vaccines (Basel). 2018. PMID: 30044370 Free PMC article. Review.
-
Pandemic preparedness through vaccine development for avian influenza viruses.Hum Vaccin Immunother. 2024 Dec 31;20(1):2347019. doi: 10.1080/21645515.2024.2347019. Epub 2024 May 28. Hum Vaccin Immunother. 2024. PMID: 38807261 Free PMC article. Review.
-
Post-exposure treatment with whole inactivated H5N1 avian influenza virus protects against lethal homologous virus infection in mice.Sci Rep. 2016 Jul 12;6:29433. doi: 10.1038/srep29433. Sci Rep. 2016. PMID: 27405487 Free PMC article.
References
-
- Yen HL, Webster RG. Pandemic influenza as a current threat. Curr Top Microbiol Immunol 2009; 333:3–24. - PubMed
-
- Xu X, Subbarao K, Cox NJ, Guo Y. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 1999; 261:15–19. - PubMed
-
- World Organization for Animal Health . Update on highly pathogenic avian influenza in animals (type H5 and H7). Available at http://www.oie.int/downld/AVIAN%20INFLUENZA/A_AI‐Asia.htm (Accessed 6 February 2012).
-
- World Health Organization . Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. 2011. Available at http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_tabl... (Accessed 6 February 2012).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical